-
1Academic Journal
Συγγραφείς: T. R. Gvindzhiliya, I. M. Kuzmina, E. V. Klychnikova, E. V. Tazina, A. A. Kochetova, N. A. Muradyan, A. S. Bogdanova, Т. Р. Гвинджилия, И. М. Кузьмина, Е. В. Клычникова, Е. В. Тазина, А. А. Кочетова, Н. А. Мурадян, А. С. Богданова
Πηγή: Transplantologiya. The Russian Journal of Transplantation; Том 16, № 3 (2024); 328-336 ; Трансплантология; Том 16, № 3 (2024); 328-336 ; 2542-0909 ; 2074-0506
Θεματικοί όροι: гемостаз, antiplatelet therapy, glycoprotein IIb/IIIa platelet receptor inhibitors, hemostasis, антиагрегантная терапия, ингибиторы гликопротеиновых IIb/IIIa рецепторов тромбоцитов
Περιγραφή αρχείου: application/pdf
Relation: https://www.jtransplantologiya.ru/jour/article/view/914/883; https://www.jtransplantologiya.ru/jour/article/view/914/890; Bergmark BA, Mathenge N, Merlini PA, Lawrence-Wright MB, Giugliano RP. Acute coronary syndromes. Lancet. 2022;399(10332):1347–1358. PMID: 35367005 https://doi.org/10.1016/S0140-6736(21)02391-6; Sharma R, Kumar P, Prashanth SP, Belagali Y. Dual Antiplatelet therapy in coronary artery disease. Cardiol Ther. 2020;9(2):349–361. PMID: 32804330 https://doi.org/10.1007/S40119-020-00197-0; Hamm CW, Bassand JP, Agewall S, Bax J, Boersma E, Bueno H, et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2011;32(23):2999–3054. PMID: 21873419 https://doi.org/10.1093/eurheartj/ehr236; Ускач Т.М., Терещенко А.С. Современная антитромбоцитарная терапия при чрескожном коронарном вмешательстве. Как сделать правильный выбор? Рациональная фармакотерапия в кардиологии. 2020;16(6):1017–1023. https://doi.org/10.20996/1819-6446-2020-11-12; Berwanger O, Nicolau JC, Carvalho AC, Jiang L, Goodman S, Nicholls SJ, et al. Ticagrelor versus clopidogrel after fibrinolytic therapy in patients with STelevation myocardial infarction: rationale and design of the ticagrelor in patients with ST elevation myocardial infarction treated with thrombolysis (TREAT) trial. Am Heart J. 2018;202:89–96. PMID: 29908420 https://doi.org/10.1016/j.ahj.2018.02.017; Altersberger VL, Sturzenegger R, Räty S, Hametner C, Scheitz JF, Moulin S, et al. Prior dual antiplatelet therapy and thrombolysis in acute stroke. Ann Neurol. 2020;88(4):857–859. PMID: 32686168 https://doi.org/10.1002/ANA.25850; Попова Л.В., Аксенова М.Б., Хлевчук Т.В. Антиагрегантная терапия в кардиологии. Клиническая медицина. 2016;94(10):729–736. https://doi.org/10.18821/0023-2149-2016-94-10-729-736; Морозова Т.Е., Вартанова О.А. Антиагреганты в лечении ишемической болезни сердца. Русский медицинский журнал РМЖ. 2007;28:2130.; Deng L, Jia HZ, Li MC, Zhu W. Comparison of the effect of ticagrelor combined with tirofiban versus clopidogrel combined with tirofiban on inflammation response and prognosis of patients with unstable angina pectoris in long term follow-up. Kaohsiung J Med Sci. 2021;37(11):1010–1015. PMID: 34338425 https://doi.org/10.1002/KJM2.12421; Layne K, Ferro A. Antiplatelet therapy in acute coronary syndrome. Eur Cardiol. 2017;12(1):33–37. PMID: 30416549 https://doi.org/10.15420/ECR.2016:34:2; Yang M, Huo X, Miao Z, Wang Y. Platelet glycoprotein IIb/IIIa receptor inhibitor tirofiban in acute ischemic stroke. Drugs. 2019;79(5):515–529. PMID: 30838514 https://doi.org/10.1007/S40265-019-01078-0; Blanchart K, Heudel T, Ardouin P, Lemaitre A, Briet C, Bignon M, et al. Glycoprotein IIb/IIIa inhibitors use in the setting of primary percutaneous coro nary intervention for ST elevation myocardial infarction in patients pre-treated with newer P2Y12 inhibitors. Clin Cardiol. 2021;44(8):1080–1088. PMID: 34114653 https://doi.org/10.1002/CLC.23654; Deng L, Jia HZ, Li MC, Zhu W. Comparison of the effect of ticagrelor combined with tirofiban versus clopidogrel combined with tirofiban on inflammation response and prognosis of patients with unstable angina pectoris in long term follow-up. Kaohsiung J Med Sci. 2021;37(11):1010-1015. PMID: 34338425 https://doi.org/10.1002/KJM2.12421; Li F, Wang S, Wang L, Liu F, Meng Z, Liu J. The effects of ticagrelor combined with tirofiban on coagulation function, serum myocardial injury markers, and inflammatory factor levels in patients with acute myocardial infarction after percutaneous coronary intervention. Comput Math Methods Med. 2022;2022:4217270. PMID: 35529262 https://doi.org/10.1155/2022/4217270; Fu X, Hao Q, Jia X, Fan W, Gu X, Wu W, et al. Effect of tirofiban plus clopi dogrel and aspirin on primary percutaneous coronary intervention via transradial approach in patients with acute myocardial infarction. Chin Med J (Engl). 2008;121(6):522–527. PMID: 18364139; Jiang Z, Zhang R, Sun M, Liu Q, Wang S, Wang W, et al. Effect of clopidogrel vs ticagrelor on platelet aggregation and inflammation markers after percutaneous coronary intervention for ST-elevation myocardial infarction. Can J Cardiol. 2018;34(12):1606–1612. PMID: 30527148 https://doi.org/10.1016/J.CJCA.2018.08.024; Xie ZJ, Xin SL, Chang C, Zhou H-J, Zhao X-F, Jiao F-H et al. Combined glycoprotein IIb/IIIa inhibitor therapy with ticagrelor for patients with acute coronary syndrome. PLoS One. 2021;16(2):e0246166. PMID: 33529262 https://doi.org/10.1371/journal.pone.0246166; Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361(11):1045–1057. PMID: 19717846 https://doi.org/10.1056/NEJ-MOA0904327; Liu Y, Liu H, Hao Z, Geng G, Chen Q, Han W, et al. Efficacy and safety of different doses of tirofiban combined with ticagrelor on diabetic patients with AMI receiving in emergency percutaneous coronary intervention (PCI). Int J Clin Exp Med. 2015;8(7):11360–11369. PMID: 26379951; https://www.jtransplantologiya.ru/jour/article/view/914
-
2Academic Journal
Συγγραφείς: A. Tereshchenko S., Е. Merkulov V., A. Samko M., А. Терещенко С., Е. Меркулов В., А. Самко Н.
Πηγή: Rational Pharmacotherapy in Cardiology; Vol 15, No 6 (2019); 918-927 ; Рациональная Фармакотерапия в Кардиологии; Vol 15, No 6 (2019); 918-927 ; 2225-3653 ; 1819-6446
Θεματικοί όροι: eptifibatide, glycoprotein IIb/IIIa receptor inhibitors, no-reflow, myocardial infarction, manual thrombus aspiration, эптифибатид, ингибиторы гликопротеиновых IIb/IIIa рецепторов, лечение no-reflow, инфаркт миокарда, мануальная тромбоэкстракция
Περιγραφή αρχείου: application/pdf
Relation: https://www.rpcardio.com/jour/article/view/2085/1900; Чазов Е.И., ред. Руководство по кардиологии. Заболевания сердечно-сосудистой системы. Том 3. М.: Практика; 2014.; Ощепкова Е.В., Ефремова Ю.Е., Карпов Ю.А. Заболеваемость и смертность от инфаркта миокарда в Российской Федерации в 2000-2011. Терапевтический Архив. 2013;(4):4-10.; Смертность населения по причинам смерти в 2018 году. Федеральная служба государственной статистики. [цитировано 04.12.2019]. Доступно на: https://www.gks.ru/storage/mediabank/demo24-2.xls.; Алекян Б.Г., Григорян А.М., Стаферов А.В., Карапетян Н.Г. Эндоваскулярная диагностика и лечение в Российской Федерации (2018). Эндоваскулярная Хирургия. 2019;(6):2.; Ibanez B., James S., Agewall S., et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2018;(39):119-177. DOI:10.1093/eurheartj/ehx792.; Терещенко А.С., Меркулов Е.В., Шахнович Р.М., Самко А.Н. Мануальная тромбоэкстракция у больных с острым инфарктом миокарда с подъемом сегмента ST. Атеротромбоз. 2016;(1):39-50. DOI:10.21518/2307-1109-2016-1-39-49.; Antman E.A., Cohen M., Bernink P.J., et al. The TIMI Risk Score for Unstable Angina/Non-ST Elevation MI. JAMA. 2000;(284):835-42. DOI:10.1001/jama.284.7.835.; Gibson C.M., Cannon C.P., Murphy S.A., et al. Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs. Circulation. 2000;101(2):125-30. DOI:10.1161/01.cir.101.2.125.; Van de Werf F., Bax J., Betriu A., et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology. Eur Heart J. 2008;(29):2909-45. DOI:10.1016/s0195-668x(02)00618-8.; Vlaar P.J., Svilaas T., van der Horst I.C., et al. Cardiac death and reinfarction after 1 year in the Thrombus Aspiration during Percutaneous coronary intervention in Acute myocardial infarction Study (TAPAS): a 1-year follow-up study. Lancet. 2008;(371):1915-20. DOI:10.1016/s01406736(08)60833-8.; Francesco B., De Vita M., Gu Y.L., et al. Clinical impact of thrombectomy in acute ST elevation myocardial infarction: an individual patient-data pooled analysis of 11 trials. Eur Heart J. 2009;(30):2193-203. DOI:10.1093/eurheartj/ehp348.; El-Jack S.S., Suwatchai P., Stewart J.T., et al. Distal embolization during native vessel and vein graft coronary intervention with a vascular protection device: predictors of high-risk lesions. J Interv Cardiol. 2007;(20):474-80. DOI:10.1111/j.1540-8183.2007.00308.x.; Frobert O., Lagerqvist B., Olivecrona G.K., et al. Thrombus Aspiration during ST-Segment Elevation Myocardial Infarction. N Engl J Med. 2013;(369):1587-97. DOI:10.1056/nejmoa1308789.; Jolly S.S., Cairns J., Yusuf S., et al. Design and rationale of the TOTAL trial: A randomized trial of routine aspiration ThrOmbecTomy with percutaneous coronary intervention (PCI) versus PCI ALone in patients with ST-elevation myocardial infarction undergoing primary PCI. Am Heart J. 2014;(167):315-21. DOI:10.1016/j.ahj.2013.12.002.; De Jong M.J., Wright S.L. New adjunctive therapy for ischemic syndromes. Crit Care Nurs Clin North Am. 1999;11(3):355-71. DOI:10.1016/s0899-5885(18)30152-7.; Певзнер Д.В., Герценберг М.З., Мазуров А.В., Власик Т.Н. О применении антиагреганта руциромаба для профилактики тромбозов при коронарной ангиопластике у больных ишемической болезнью сердца. Кардиология. 2015;55(12):125-32. DOI:10.18565/cardio.2015.12.90-98.; Махиянова Э.И., Галявич А.С. Эффективность и безопасность блокатора гликопротеиновых рецепторов IIb/III амонафрама при коронарном стентировании пациентов с острым инфарктом миокарда. Рациональная Фармакотерапия в Кардиологии. 2011;7(4):452-6. DOI:10.20996/1819-6446-2011-7-4-452-456.; Yalcin V., Tolga S.G., Koray D., et al. Effects of Bailout Tirofiban on In-Hospital Outcomes and LongTerm Mortality in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Intervention. Angiology. 2019;70(5):431-9. DOI:10.1177/0003319718808911.; Ten Berg J.M., Van't Hof A.W., Dill T., et al. Effect of early, pre-hospital initiation of high bolus dose tirofiban in patients with ST-segment elevation myocardial infarction on shortand long-term clinical outcome. J Am Coll Cardiol. 2010;55(22):2446-55. DOI:10.1016/j.jacc.2009.11.091; Van't Hof A.W., Ten Berg J., Heestermans T., et al. Prehospital initiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angioplasty (On-TIME 2): a multicentre, doubleblind, randomised controlled trial. Lancet. 2008;(372):537-46. DOI:10.1016/s01406736(08)61235-0.; Zhang Z., Li W., Wu W., et al. Myocardial reperfusion with tirofiban injection via aspiration catheter: Efficacy and safety in STEMI patients with large thrombus burden. Herz. 2018;(12). DOI:10.1007/s00059-018-4716-0.; Brener S.J., Barr L.A., Burchenal J.E., et al. Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators. Circulation. 1998;(8):734-41. DOI:10.1161/01.cir.98.8.734.; Neumann F.J., Kastrati A., Schmitt C., et al. Effect of glycoprotein IIb/IIIa receptor blockade with abciximab on clinical and angiographic restenosis rate after the placement of coronary stents following acute myocardial infarction. J Am Coll Cardiol. 2000;(35):915-21. DOI:10.1016/s07351097(99)00635-x.; Montalescot G., Barragan P., Wittenberg O., et al. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med. 2001;(334):1895-903. DOI:10.1056/NEJM200106213442503.; Mahmoudi M., Delhaye C., Wakabayashi K., et al. Integrilin in patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction. J Interv Cardiol. 2011;24(4):351-6. DOI:10.1111/j.1540-8183.2011.00632.x.; Zeymer U., Zahn R., Schiele R., et al. Early eptifibatide improves TIMI 3 patency before primary percutaneous coronary intervention for acute ST elevation myocardial infarction: results of the randomized integrilin in acute myocardial infarction (INTAMI) pilot trial. Eur Heart J. 2005;(26):1971-7. DOI:10.1093/eurheartj/ehi293.; Gibson M., Kirtane A.J., Murphy S.A., et al. TIMI Study Group Early initiation of eptifibatide in the emergency department before primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: results of the Time to Integrilin Therapy in Acute Myocardial Infarction (TITAN)TIMI 34 trial. Am Heart J. 2006;(152):668-75. DOI:10.1016/j.ahj.2006.06.003.; Akerblom A., James S.K., Koutouzis M., et al. Eptifibatide is noninferior to abciximab in primary percutaneous coronary intervention: results from the SCAAR (Swedish Coronary Angiography and Angioplasty Registry). J Am Coll Cardiol. 2010;56(6):470-5. DOI:10.1016/j.jacc.2009.10.093.; Gurm H.S., Smith D.E., Collins J.S., et al. The Relative Safety and Efficacy of Abciximab and Eptifibatide in Patients Undergoing Primary Percutaneous Coronary Intervention. J Am Coll Cardiol. 2007;51(5):529-35. DOI:10.1016/j.jacc.2007.09.053.; Протокол CORINT/ 2012. Платформа по поиску клинических исследований Clinline [цитировано 04.12.2019]. Доступно на: https://clinline.ru/reestr-klinicheskih-issledovanij/646-14.10.2013.html.; Острый инфаркт миокарда с подъемом сегмента ST электрокардиограммы. Клинические рекомендации [цитировано 04.12.2019]. Доступно на: http://cr.rosminzdrav.ru/#!/schema/135.; Belle L., Cayla G., Cottin Y., et al. French Registry on Acute ST-elevation and non−ST-elevation Myocardial Infarction 2015 (FAST-MI 2015). Design and baseline data. Arch Cardiovasc Dis. 2017;110(6-7):366-78. DOI:10.1016/j.acvd.2017.05.001.; Brahmajee K., Sharon-Lise T., Yongfei W., et al. Relation between door-to-balloon times and mortality after primary percutaneous coronary intervention over time: a retrospective study. Lancet. 2015;(385):1114-22. DOI:10.1016/s0140-6736(14)61932-2.; Эрлих А.Д., ГрацианскийН.А. от имени участников регистра РЕКОРД-3. Российскийрегистр острого коронарного синдрома «РЕКОРД-3». Характеристика пациентов и лечение до выписки из стационара. Кардиология. 2016;4(16):16-24. DOI:10.1016/j.gheart.2016.03.162.; Karathanos A., Lin Y., Dannenberg L., et al. Routine Glycoprotein IIb/IIIa Inhibitor Therapy in ST-Segment Elevation Myocardial Infarction: A Meta-analysis. Can J Cardiol. 2019;35(11):1576-88. DOI:10.1016/j.cjca.2019.05.003.; https://www.rpcardio.com/jour/article/view/2085